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ABSTRACT
Phenotypic and genotypic SPM and IMP metallo-β-lactamases (MBL) detection and also the deter-
mination of minimal inhibitory concentrations (MIC) to imipenem, meropenem and ceftazidime 
were evaluated in 47 multidrug-resistant Pseudomonas aeruginosa isolates from clinical specimens. 
Polymerase chain reaction detected 14 positive samples to either blaSPM or blaIMP genes, while the best 
phenotypic assay (ceftazidime substrate and mercaptopropionic acid inhibitor) detected 13 of these 
samples. Imipenem, meropenem and ceftazidime MICs were higher for MBL positive compared to 
MBL negative isolates. We describe here the SPM and IMP MBL findings in clinical specimens of P. 
aeruginosa from the University Hospital of Botucatu Medical School, São Paulo, Brazil, that reinforce 
local studies showing the high spreading of blaSPM and blaIMP genes among Brazilian clinical isolates.
Keywords: Pseudomonas aeruginosa; drug resistance, bacterial; carbapenems; metalloproteins; poly-
merase chain reaction.
important to implement infection control 
measures, and to apply the most appropriate 
therapy.6,7 Several studies analyzed different 
substrata and MBL inhibitors associations 
researching MBL-producing bacteria,7,8 but 
no standardization to MBL detection has 
been published so far by guidelines, namely 
Clinical and Laboratory Standards Institute 
(CLSI). E-test strips have also been employed 
to detect MBL enzymes.8 In Brazil, São Paulo 
metallo-β-lactamase (SPM) and imipen-
emase (IMP) are prevalent in P. aerugino-
sa.7,9,10 In the present study, we aimed to de-
tect MBL production in clinical specimens of 
P. aeruginosa isolated from patients of a Bra-
zilian public tertiary hospital, and providing 
data to epidemiology of MBL in Brazil.
Forty-seven P. aeruginosa strains isolated 
between 2006 and 2007 were evaluated. The 
isolates were recovered from clinical specimens 
collected from patients attended at University 
Hospital of Botucatu Medical School, São Paulo 
State, Brazil, a regional reference tertiary hospi-
tal. Isolates were chosen due to their multidrug-
resistant profile, according to disk-diffusion 
susceptibility test and CLSI cutoffs,11 and the 
sole susceptibility to polymyxin B, confirmed by 
E-test (AB Biodisk) strips [minimal inhibitory 
INTRODUCTION
The most common cause of Gram-negative 
bacterial resistance to β-lactam antimicro-
bial agents is the β-lactamases production, 
which is highly diversified and spread in sev-
eral bacteria.1,2 Metallo-β-lactamase (MBL) 
belongs to Group 3 of enzymes proposed by 
Bush and Jacoby,2 and shows ability to hydro-
lyze carbapenems instead of cephalosporins, 
cephamycins, and penicillins. Contrasting to 
serine-β-lactamases, MBL has poor ability 
to hydrolyze monobactams.2 Pseudomonas 
aeruginosa is one of the most common causes 
of nosocomial infections, persisting at hos-
pital environment and acquiring mobile ele-
ments of resistance.3 The emergency of MBL 
in clinical isolates of P. aeruginosa is wor-
risome, due to the reduction of therapeutic 
options and the spreading ability of this bac-
terium. In addition, longer length of hospital 
stay and high mortality rates are associated 
to MBL producing P. aeruginosa infections.3 
Besides β-lactam resistance, P. aeruginosa 
susceptible only to colistin or polymyxin B 
has been described3-5 in several infectious 
processes, which demand the increase use of 
these drugs. An accurate, easy-to-perform 
and fast phenotypic test to detect MBL is 
BJID-5-agosto.indd   478 27/09/11   09:59
Este é um artigo Open Access sob
 a licença de CC BY-NC-ND
479Braz J Infect Dis 2011; 15(5):478-481
concentrations (MIC) ranging from 0.094 to 2; MIC50: 0.5; 
MIC90: 1.5 µg/mL; 100% susceptible]. MICs were determined 
(in duplicate) by microdilution broth method for imipenem 
(ABL), meropenem (Astra Zeneca) and ceftazidime (Nova-
Farma); quality controls were performed with Escherichia coli 
ATCC 25922 and P. aeruginosa ATCC 27853 strains. MBL 
phenotypic detection was evaluated by the double-disk syner-
gy test (DDST) with imipenem or ceftazidime disks (Oxoid) 
as substrata, and mercaptopropionic acid (Sigma-Aldrich), 
mercaptoacetic acid (Sigma-Aldrich), or ethylenediamine 
tetra-acetic acid (EDTA, Sigma-Aldrich) as MBL inhibitors, 
according to Picão et al.7 Genotypic detection targeting to the 
blaSPM and blaIMP genes was carried out by polymerase chain 
reaction (PCR), according to protocols published elsewhere.9 
Positive and negative quality control strains were included to 
assess the quality of phenotypic and genotypic assays. Stu-
dent’s t test was carried out to compare the median MIC of 
positive and negative MBL strains; sensitivity and specificity 
were calculated for the different substrata antimicrobials and 
MBL inhibitors assessed in the DDST; p-values below 0.05 
were considered statistically significant. The study was ap-
proved by the local Ethics Committee (Protocol 2886-2008).
Forty-seven isolates of P. aeruginosa were analyzed, 
from urine (17), blood (5), and various other specimens 
(25). The distribution of isolates across the hospital was 
diversified, being, even in low numbers, mostly isolated 
from Emergency Unit and Urology Wards (5 each), and 
Central Intensive Care Unit (4). MIC values range 
(and MIC that inhibited the growth of 90% of the strains, 
MIC90) for imipenem, meropenem and ceftazidime, were, 
respectively, 16 to 512 (512); 16 to > 512 (512); 4 to > 512 
(512 µg/mL). MIC median for MBL-positive strains were 
significantly higher than those MIC for MBL-negative 
strains (p < 0.0001), for each drug: imipenem, meropenem 
and ceftazidime (Figure 1). Polymyxin B MIC median also 
showed difference between MBL-positive and -negative 
strains (0.98 vs. 0.66 µg/mL, respectively; p = 0.0097). MBL 
genotypic detection was carried out with specific primers 
for blaSPM and blaIMP genes. Fourteen (29.8%) isolates in 47 
samples were either blaSPM or blaIMP positive. blaSPM gene ac-
counted for 71% (10/14) positive MBL strains, while blaIMP 
was detected in 29% (4/14). DDST employing mercapto-
propionic acid and ceftazidime showed the best association 
to PCR results, with sensitivity of 92.8% and specificity of 
100%. MBL-positive P. aeruginosa strains were isolated 
from different clinical sources (urine, blood, and other 
biological fluids) and from several wards: Gastric Surgery, 
Gastroenterology, Intensive Care Unit, Intern Medicine, 
Orthopedics, Urology and Agreement Ward.
P. aeruginosa is an important nosocomial agent, and 
several resistance mechanisms have been related on this 
microorganism;12,13 MBL has been emerging as a worrying 
resistance mechanism in this and in several other Gram-
negative rods.2 β-lactamases are currently classified by two 
ways: based on the amino acid sequence (molecular classifi-
cation) or based on the hydrolytic and inhibition properties 
(functional classification).2 According to molecular classifi-
cation β-lactamases are grouped into class A, B, C and D. 
While class A, C and D enzymes are characterized to utilize 
serine for β-lactam hydrolysis, class B enzymes are metal-
loenzymes, that use divalent cations as cofactors to substrate 
hydrolysis.2 Functional classification divides β-lactamases 
enzymes into 3 groups: group 1, cephalosporinases; group 
2, the largest one, which contains enzymes that hydrolyses 
penicillins, cephalosporins, monobactams, carbenicillin, 
cloxacillin, and carbapenems; and group 3, metallo-carbap-
enemase. Colistin-only susceptible P. aeruginosa is a relative-
ly contemporary issue, once carbapenems remained as effec-
tive therapeutic choice until the carbapenemases emergence 
on the last two decades.7,8,14 Investigating MBL-encoding 
genes, we found isolates carrying blaSPM and blaIMP genes that 
together correspond to 29.8% of evaluated samples. In Bra-
zil, the dissemination of P. aeruginosa carrying blaSPM gene 
has been reported throughout from several regions,15,16 and 
SPM is the prevalent MBL among the isolates, although oth-
er enzymes have also been described, but with low frequen-
cy.9,10,16,17 SPM carbapenemase was the main mechanism that 
conferred resistance to ceftazidime on ceftazidime-resistant 
P. aeruginosa isolated from bloodstream infections.10 MBL 
rate found here is higher than that one reported by Viana 
Vieira et al.14 (7.5%), but it is lower than those published by 
other Brazilian researchers (35.9 to 80.4%).9-11,18-20 Zavascki 
et al.3 found 30 P. aeruginosa only susceptible to polymyxin 
B among 86 MBL producing strains and the blaSPM gene 
was detected in all the 14 strains randomly selected, and 
Figure 1: Comparison between MIC of MBL-negative and 
positive- P. aeruginosa strains. o represents each isolate; 
horizontal bars represent average values. CAZ, ceftazidime; 
IMP, imipenem; MEM, meropenem.
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Gräf et al.19 also detected the blaSPM gene in strains only sus-
ceptible to polymyxin B, both from Brazilian hospitals. Our 
data are in accordance to these studies, showing that SPM is 
the prevalent MBL among Brazilian P. aeruginosa isolates. The 
lower frequency of MBL in our patient population might be 
the result of our inclusion criteria (only susceptibility to poly-
myxin B), once that resistance to imipenem and meropenem 
simultaneously suggests the evolvement of carbapenem resist-
ance mechanism other than the enzymatic one, such as porin 
loss and/or overexpression of efflux pumps.10 High MIC val-
ues for carbapenems and ceftazidime are associated to MBL 
production, and this may be a useful tool to differentiate from 
other resistance mechanism, such as efflux pumps or chro-
mosomal inducible AmpC β-lactamase.1 Recent studies con-
firm this tendency,5,9,10,12 and our data also showed this remark 
(Figure 1). Some peculiar serine-β-lactamases, such as 
GES-5, can also present hydrolytic activity against carbap-
enems in P. aeruginosa isolates; this activity is, however, 
lower than that one presented by MBL-encoding genes iso-
lates, as recently reported in a Brazilian study.10 Resistance 
to other antimicrobial agent classes12,13 reduces the thera-
peutic options to manage multidrug-resistant P. aeruginosa 
clinical isolates, and it seems to be even more recurrent to 
employ last resource drugs, such as polymyxins, to treat 
these infections. Polymyxin B showed efficacy against all 
of the isolates here evaluated. Similar observation was re-
ported by Lee et al.5 who studied 17 colistin-only sensitive 
isolates from Korea (MIC ranging from 0.5-2.0 μg/mL). 
In imipenem-resistant P. aeruginosa strains isolated from 
a Brazilian tertiary care university hospital, polymyxin B 
showed great activity (100% susceptible; MIC90 ≤ 0.5 mg⁄L).9 
However, we can wonder how much longer these bacte-
ria will persist susceptible to these remaining drugs if this 
selective pressure goes on. Comparing different pheno-
typic tests to detect MBL, we found that ceftazidime disk 
and mercaptopropionic acid association, in a double disk syn-
ergy test, was the most sensitive and specific assay, as it was re-
ported by Picão et al.7 We observed that all other combinations 
of substrata and inhibitors (imipenem and mercaptopropi-
onic acid; imipenem and mercaptoacetic acid; imipenem and 
EDTA; ceftazidime and mercaptoacetic acid; ceftazidime 
and EDTA) showed maximum specificities (100%), but low 
sensitivity to these combinations (zero to 71.4%), restricting 
their utilization. In spite of the high cost, MBL E-test strips 
can be employed to detect the MBL-producing P. aeruginosa 
due its high sensibility and specificity.8 Despite the recom-
mendation for screening and confirming carbapenemase pro-
duction in Enterobacteriaceae, CLSI document M100-S2011 
made no mention of detecting this enzyme on non-fermen-
tative Gram-negative bacteria. Early identification of MBL in 
clinical specimens is important to provide correct antimicro-
bial therapy guidance, once appropriate therapy implemen-
tation can nullify the worst prognostic of MBL producing 
P. aeruginosa.3 When detected, it is possible to avoid the 
dissemination of such strains among patients7-9 and to 
avoid the MBL genetic determinants spread to differ-
ent species of Gram-negative bacteria, as Enterobacte-
riaceae.6 The contention of MBL producing P. aerugi-
nosa is highly recommended, because patient-to-patient 
transmission may lead these strains to be endemic in 
such institution3 or among different hospitals.15-17 In 
Brazil, Gales et al.16 reported the spreading of blaSPM-
producing P. aeruginosa clone throughout the coun-
try. The non-centralized distribution of positive MBL 
P. aeruginosa from Hospital of Botucatu Medical School 
(i.e., the recovering of MBL P. aeruginosa from hospital-
ized patients from several wards) suggests the non-clonal 
spreading of P. aeruginosa strains, although further mo-
lecular analyses are necessary to confirm this hypothesis. 
Our results contribute to the study of MBL epidemiology 
in Brazil, mainly to blaSPM spreading. It is worthwhile to 
emphasize that, after restricted by more than ten years to 
Brazilian hospitals, SPM seems to become a global chal-
lenge,15,20 warning for the role of human traffic in spreading 
MBL genes.6,20
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